|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:rilpivirine
gptkb:tenofovir_alafenamide
emtricitabine
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AR18
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to active substances
concurrent use with strong CYP3A inducers
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:drugClass
|
protease inhibitor
nucleotide reverse transcriptase inhibitor
non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:form
|
gptkb:tablet
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Odefsey
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
antiretroviral therapy
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
nausea
fatigue
headache
insomnia
|
|
gptkbp:bfsParent
|
gptkb:rilpivirine
|
|
gptkbp:bfsLayer
|
6
|